Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNFRSF13B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFRSF13B ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). Suitable for binding kinetics and ELISA. |
View TNFRSF13B Products |
| Gene Delivery | TNFRSF13B Lentivirus Premade Particles Full-length ORF for stable cell line generation. Perfect for flow cytometry validation and cell-based functional assays. |
View TNFRSF13B Products |
| Benchmark Ab | Anti-TNFRSF13B Recombinant Antibody Biosimilar sequence based on clinical benchmark (e.g., Telitacicept-derived positive control). Recombinant expression ensures batch-to-batch consistency. |
View TNFRSF13B Products |
| Validator | TNFRSF13B siRNA Set Target-specific gene knockdown for functional validation and specificity controls. |
View TNFRSF13B Products |
| Related Target A | TNFSF13 (APRIL) Natural ligand of TNFRSF13B. Critical for screening ligand-blocking antibodies and fusion protein therapeutics. |
View TNFSF13 Products |
| Related Target B | TNFSF13B (BAFF) Co-ligand sharing the pathway with TNFRSF13B. Essential for selectivity profiling and dual-targeting validation. |
View TNFSF13B Products |
| Related Target C | TNFRSF17 (BCMA) Homologous receptor sharing ligands (BAFF/APRIL). Critical for off-target counter-screening and dual-CAR-T development. |
View TNFRSF17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual-Ligand (BAFF/APRIL) Blocking Validation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity to confirm cross-species blocking efficiency. |
| Isoform Specificity (TACI-Long vs. TACI-Short) | Sequence-verified recombinant proteins covering specific extracellular domain truncations to differentiate splice-variant binding. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included as reliable positive controls for binding and functional assays. |
| False Positives in Cell Assays | Validated siRNA sets included for target knockdown verification to confirm specificity of lead candidates. |
Live TNFRSF13B/CD267 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFRSF13B (TACI) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-target fusion proteins and dual-targeting CAR-T therapies. TNFRSF13B plays a pivotal role in B-cell autoimmune diseases and plasma cell malignancies due to its interaction with both BAFF and APRIL. As first-generation therapies like Telitacicept (TACI-Fc fusion) demonstrate robust clinical efficacy in systemic lupus erythematosus (SLE) and IgA nephropathy, the next wave of R&D is targeting bispecific modalities and highly selective engineered receptors to avoid decoy receptor shedding and optimize tissue penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fc-Fusion Protein (TACI-Fc) | RemeGen, Biogen | SLE, IgA Nephropathy, RA | Ligand-binding competition assays (Requires high-purity BAFF and APRIL recombinant proteins) |
| CAR-T (BCMA/TACI Dual) | Academic institutions, Biotech startups | Multiple Myeloma, CLL | Cell-surface expression validation (Requires Lentivirus for stable cell line construction and flow cytometry) |
| Monoclonal/Bispecific Antibodies | Clinical-stage biopharma | Autoimmune diseases | Epitope mapping & affinity determination (Requires sequence-verified TNFRSF13B ECD proteins) |